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Development of stem cell therapies to treat cardiovascular disease
is limited by the ability to regulate stem cell differentiation and by
poor cell survival once grafted to sites of damage in the heart [1].
SUR2A belongs to a group of “atypical” ABC proteins as, although
possessing a structure of an ABC protein, it does not seem to mediate
transport. Instead, SUR2A binds to inward rectiﬁer Kir6.2 to form
cardiac sarcolemmal ATP-sensitive K+ channels. The binding of SUR2A
to Kir6.2 serves a dual purpose: 1) it allows translocation of the
channel to the sarcolemma and 2) contributes to the channel
regulation (reviewed in ref. [2]). In vivo, KATP channels exist as a
multiprotein complex that, besides pore-forming Kir6.1/Kir6.2 and
regulatory SUR2A subunits, also contain a string of glycolytic and ATP-
producing enzymes including creatine kinase, GAPDH and M-LDH. It
has been shown that the changes in levels of SUR2A alone have a
profound effect on myocardial susceptibility to different types of
metabolic stresses including hypoxia, ischemia, ischemia-reperfusion
and stimulation with β-adrenergic agonists (reviewed in ref. [3]).
Increase in intracellular SUR2A raises the number of fully-assembled
cardioprotective KATP channels resulting in 1) earlier opening of KATP
channels in response to stress and 2) increased subsarcolemmal ATP
due to increased recruitment of creatine kinase and glycolytic
enzymes to the KATP channel protein complex. Improved timing of
KATP channel opening as well as increased subsarcolemmal production
of ATP seems to mediate cardioprotection afforded by SUR2A [3]. The
efﬁcacy and safety of SUR2A led to suggestion that manipulation of its
expression in cardiac tissue could be a promising therapeutic strategy
against ischemic heart disease [3]. On the other hand, it has been also
shown that cardiac stem cells regenerate infarcted myocardium and
improve cardiac function [1]. Whether SUR2A-based therapeutic
strategy of heart ischemia is compatible/complementary with stem
cell therapy is at the present unknown. To assess possible relationship
between SUR2A and cardiac stem cells, we have collected mouse fetal
hearts at E12.5 stage (for details of heart harvesting at this stage see
ref. [4]) and infected them with adenovirus containing SUR2A (AV-
SUR2A) or luciferase (control; method of infection is described in ref.
[5]). Hearts were used 24 h later for biochemical assessments.
Infection of the heart with AV-SUR2A increased SUR2A mRNA levels
for ~10 times showing that infection was sufﬁcient to produce
signiﬁcant increase in SUR2A (Fig. 1). At the same time, expression of
genes indicating differentiation of cardiomyocytes, as measured by
quantitative real time RT-PCR (for detailed methodology see ref. [5]),
was dramatically decreased; troponin C for ~30 times and GATA 4
for ~4 times. BMZ, a housekeeping gene, was not affected at all (Fig.1).
These ﬁndings suggest that SUR2A shifted embryonic cardiomyocytes
towards less differentiated state. It is well established that ERK1/2
pathway is responsible for heart embryonic development (reviewed
in ref. [6]). In order to determine whether SUR2A affects this signaling
pathway we have measured phosphorylation of ERK following
infection with AV-SUR2A. Using Western blotting (for details of
methodology see ref. [4]), we have found signiﬁcant decrease in ERK1/
2 phosphorylation in hearts infected by AV-SUR2A (Fig. 2), which was
associated with dramatic increase in expression of stem cell
pluripotency marker mRNAs (Oct-4, Sox2 and NANOG; Fig. 2)
whose abundance is known to promote non-differentiating, prolif-
erative growth in cardiac and other tissues [7]. It is well established
that pluripotent stem cells can be generated from somatic cells by
expression of reprograming factors, such as Oct-4 and Sox2. It has
been proposed that it's the ratio of these genes to one another that
really matters in reprogramming [8]. Here we have found that
although SUR2A increased the expression of all 3 genes, the effect
was greatest for Sox2 and Oct-4 strongly suggesting that cardiomyo-
cytes were indeed reprogrammed into stem cells. Ratio of Sox2/Oct-4/
NANOG seems to be a hallmark of cardiomyocyte non-differentiation
and recent demonstration that NANOG over-expression raises Oct-4
and Sox2 and hinders cardiomyocyte differentiation strongly supports
our data [9]. These results suggest that SUR2A “tip” cardiomyocytes
towards a primed state capable of non-differentiating growth which is
characteristic to cardiomyocyte precursor cells. When considering
that, in addition to ﬁndings from this study, increased SUR2A levels
are also efﬁcient in protecting both embryonic and adult heart cells
against severe metabolic stress (including ischemia; refs. [3,5]), this
protein seems perfect to be used as a tool to 1) keep stem cells into
non-differentiated state, while 2) increasing their resistance to
metabolic stress. Stem cells overexpressing SUR2A would be easier
to maintain in non-differentiated state, while such cells would
survive better when they are grafted to treat ischemia/myocardial
infarction. As methodologies securing long-lasting expression of a
gene are now well developed [10], there are no any technical
obstacles in obtaining cardiac stem cells overexpressing SUR2A for
therapeutic purposes. The properties of SUR2A to keep stem cells
non-differentiated and to increase their resistance tometabolic stress
suggest that SR2A overexpressing stem cells deserve to be seriously
tested as a potential therapy against heart ischemia, including the
myocardial infarction.
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Fig. 1. Infection of fetal heart by SUR2A results in decreased expression of cardiomyocyte expression markers. Fetal hearts were collected at E12.5 stage. Original real time RT-PCR
progress curves for SUR2A, troponin C, GATA 4 and housekeeping gene BMZ and corresponding graphs depicting cycling threshold. Each bar represents mean ± S.E.M. (n = 3).
*P b 0.05. Infection of heart with SUR2A increased SUR2AmRNA levels for ~10 times and decreased troponin C and GATA 4 mRNA for ~30 and ~4 times. Infectionwith SUR2A did not
affect BMZ at all.
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Fig. 2. Infection of fetal heart by SUR2A results in suppressed ERK activity and heart shifted towards less differentiated state. Fetal hearts were collected at E12.5 stage. A. Original
Western blotting and corresponding graphs of fetal hearts infectedwith luciferase (control; luciferasewas used as a control as we have determined that infectionwith luciferase does
not affect phospho- or total ERK1/2) and SUR2A. While total ERK1/2 was not affected by SUR2A, phosphorylation of ERK1/2 was. Each bar represents mean ± S.E.M. (n = 3; n is
deﬁned as the number of infected fetal hearts). *P b 0.05. B. Original real time RT-PCR progress curves for Oct4, Sox 2 and nanog and corresponding graphs depicting cycling
threshold. Each bar represents mean ± S.E.M. (n = 3). *P b 0.05.
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